Homepage > Company > Media > Pharma News > 2018 > Mylan gets FDA nod for cost-saving HIV combo

Mylan gets FDA nod for cost-saving HIV combo

The U.S. FDA approved Mylan’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate), a triple combo once-daily HIV treatment for adult and pediatric patients who weigh at least 88 lbs.

This marks the third HIV approval for Mylan. The approval of Symfi comes after the FDA's recent approval of two Mylan antiretrovirals (ARVs): Cimduo (lamivudine and tenofovir disoproxil fumarate) and Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate).

Efavirenz tablets are a generic form of Bristol-Myers Squibb’s Sustiva. Lamivudine tablets are the generic version of ViiV Healthcare's Epivir.

According to Mylan, all ARV regimens are being offered at a significant discount to the price of competing products to bring cost savings to the $20 billion U.S. ARV market.

Apr 2, 2018

https://www.pharmamanufacturing.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...